Several HDAC inhibitors (HDACIs), such as trichostatin A (TSA) and butyrate, have been utilized to treat skeletal muscle atrophy, effectively inhibiting the expression of MuRF1 and MAFbx and alleviating skeletal muscle atrophy in a mouse model [192, 193]. The gene discussed is TRIM63; the disease is muscle atrophy.